DCAL NSE filing

Dishman Carbogen Amcis Q2FY27 Results: Net Revenue Down 22.3% YoY to ₹507.4 Crore

The RealCase readHigh impact Negative

Dishman Carbogen Amcis reported Q2FY27 Net Revenue of ₹507.4 crore, down 22.3% YoY. EBITDA fell 69.1% to ₹46 crore with margins at 9.1%. H1FY27 Net Revenue was ₹1,185 crore, down 12.9% YoY, and EBITDA decreased 63.4% to ₹106 crore. CDMO revenue declined, while Marketable Molecules revenue saw a slight increase.

Why it matters

The substantial decrease in revenue and EBITDA, along with margin contraction, directly impacts the company's financial health and investor perception, warranting a high impact assessment.

The market read

The company reported a significant year-on-year decline in both revenue and profitability for the quarter and half-year ended September 30, 2026, indicating a negative financial performance.

Dishman Carbogen Amcis Limited (DCAL) has announced its un-audited financial results for the second quarter and half year ended September 30, 2026. The company presented an investor presentation detailing these results.

For the second quarter (Q2FY27), Net Revenue stood at ₹507.4 crore (₹5,073.7 million), marking a 22.3% decrease compared to ₹652.7 crore (₹6,526.5 million) in Q2FY26. EBITDA for the quarter was ₹46 crore (₹459.6 million), a significant drop of 69.1% from ₹148.9 crore (₹1,488.9 million) in the same period last year, with the EBITDA margin decreasing to 9.1% from 22.8% in Q2FY26. The CDMO segment revenue saw a decline of 23.7% YoY to ₹388.7 crore (₹3,887.5 million), while Marketable Molecules (MM) revenue increased by 6.6% YoY to ₹118.6 crore (₹1,186.2 million).

For the half year ended September 30, 2026 (H1FY27), Net Revenue was ₹1,185.0 crore (₹11,850.1 million), a decrease of 12.9% compared to ₹1,360.7 crore (₹13,607.0 million) in H1FY26. EBITDA for H1FY27 was ₹106.0 crore (₹1,060.4 million), down 63.4% from ₹289.6 crore (₹2,895.7 million) in H1FY26, with the EBITDA margin at 8.9% compared to 21.3% in H1FY26. CDMO revenue for H1FY27 decreased by 17.1% YoY to ₹929.0 crore (₹9,290.4 million), while MM revenue increased by 6.6% YoY to ₹256.0 crore (₹2,559.7 million).

The decrease in revenue and profitability is attributed to lower development revenue in the CDMO segment and rescheduling of project deliverables worth approximately CHF 10 million to H2FY27. The MM segment's performance was impacted by lower revenue from the vitamin segment, partially offset by higher Quaternary compounds sales. Capital expenditure during Q2 FY2027 was USD 5.4 million and USD 10.3 million during H1FY2027.

Filing to action

What to do with a filing like this

Dishman Carbogen Amcis Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Dishman Carbogen Amcis Limited. Read the original for the full detail.

View original filing